GeoVax Labs (GOVX) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on vaccines and immunotherapies for infectious diseases and solid tumor cancers using proprietary platforms.

• Lead programs include GEO-MVA (MVA-based vaccine for mpox and smallpox) and Gedeptin® (gene-directed therapy for head and neck cancers).

• GEO-MVA is advancing under expedited regulatory pathways in Europe, with a pivotal Phase 3 trial planned for late 2026.

• Gedeptin® completed Phase 1/2 trials; a Phase 2 trial in combination with immune checkpoint inhibitors is planned for H2 2027.

• Strategy includes advancing products through clinical testing and seeking partnerships or licensing for commercialization.

Financial performance and metrics

• No product revenue to date; revenues have come from government grants and collaborations.

• Net loss of $21.5 million for 2025 and $9.7 million for the six months ended June 30, 2026.

• Cash and cash equivalents were $3.1 million as of June 30, 2026, sufficient to fund operations into October 2026.

• Research and development expenses were $18.1 million in 2025, down from $23.7 million in 2024.

• Received a going concern opinion from auditors due to recurring losses and need for additional funding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; proceeds from any cash exercise of warrants will be used for general corporate purposes and working capital.

• Pending use, proceeds will be invested in high-quality, short-term, interest-bearing securities.